BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18431519)

  • 1. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
    Tiedemann RE; Mao X; Shi CX; Zhu YX; Palmer SE; Sebag M; Marler R; Chesi M; Fonseca R; Bergsagel PL; Schimmer AD; Stewart AK
    J Clin Invest; 2008 May; 118(5):1750-64. PubMed ID: 18431519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.
    Misiewicz-Krzeminska I; Sarasquete ME; Vicente-Dueñas C; Krzeminski P; Wiktorska K; Corchete LA; Quwaider D; Rojas EA; Corral R; Martín AA; Escalante F; Bárez A; García JL; Sánchez-García I; García-Sanz R; San Miguel JF; Gutiérrez NC
    Clin Cancer Res; 2016 Jan; 22(1):207-17. PubMed ID: 26341922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.
    Mao X; Cao B; Wood TE; Hurren R; Tong J; Wang X; Wang W; Li J; Jin Y; Sun W; Spagnuolo PA; MacLean N; Moran MF; Datti A; Wrana J; Batey RA; Schimmer AD
    Blood; 2011 Feb; 117(6):1986-97. PubMed ID: 21135258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D type does not influence cell cycle response to DNA damage caused by ionizing radiation in multiple myeloma tumours.
    Smith D; Mann D; Yong K
    Br J Haematol; 2016 Jun; 173(5):693-704. PubMed ID: 27146121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional regulation of cyclin D2 by the PKA pathway and inducible cAMP early repressor in granulosa cells.
    Muñiz LC; Yehia G; Mémin E; Ratnakar PV; Molina CA
    Biol Reprod; 2006 Aug; 75(2):279-88. PubMed ID: 16625003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
    Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
    Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-146a-5p inhibits cell proliferation and cell cycle progression in NSCLC cell lines by targeting CCND1 and CCND2.
    Li YL; Wang J; Zhang CY; Shen YQ; Wang HM; Ding L; Gu YC; Lou JT; Zhao XT; Ma ZL; Jin YX
    Oncotarget; 2016 Sep; 7(37):59287-59298. PubMed ID: 27494902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas.
    Büschges R; Weber RG; Actor B; Lichter P; Collins VP; Reifenberger G
    Brain Pathol; 1999 Jul; 9(3):435-42; discussion 432-3. PubMed ID: 10416984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
    Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
    Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.
    Schmidt M; Fernandez de Mattos S; van der Horst A; Klompmaker R; Kops GJ; Lam EW; Burgering BM; Medema RH
    Mol Cell Biol; 2002 Nov; 22(22):7842-52. PubMed ID: 12391153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyproheptadine displays preclinical activity in myeloma and leukemia.
    Mao X; Liang SB; Hurren R; Gronda M; Chow S; Xu GW; Wang X; Beheshti Zavareh R; Jamal N; Messner H; Hedley DW; Datti A; Wrana JL; Zhu Y; Shi CX; Lee K; Tiedemann R; Trudel S; Stewart AK; Schimmer AD
    Blood; 2008 Aug; 112(3):760-9. PubMed ID: 18502826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
    Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A
    Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma.
    Liu H; Huang J; Wang J; Jiang S; Bailey AS; Goldman DC; Welcker M; Bedell V; Slovak ML; Clurman B; Thayer M; Fleming WH; Epner E
    J Exp Med; 2008 Aug; 205(8):1843-58. PubMed ID: 18625744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases.
    Takano Y; Kato Y; van Diest PJ; Masuda M; Mitomi H; Okayasu I
    Am J Pathol; 2000 Feb; 156(2):585-94. PubMed ID: 10666388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
    Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin K and cyclin D1b are oncogenic in myeloma cells.
    Marsaud V; Tchakarska G; Andrieux G; Liu JM; Dembele D; Jost B; Wdzieczak-Bakala J; Renoir JM; Sola B
    Mol Cancer; 2010 May; 9():103. PubMed ID: 20459741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
    Glassford J; Rabin N; Lam EW; Yong KL
    Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.
    Bergsagel PL; Kuehl WM
    Immunol Rev; 2003 Aug; 194():96-104. PubMed ID: 12846810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of cyclin D2 is associated with increased in vivo invasiveness of human squamous carcinoma cells.
    Liu SC; Bassi DE; Zhang SY; Holoran D; Conti CJ; Klein-Szanto AJ
    Mol Carcinog; 2002 Jul; 34(3):131-9. PubMed ID: 12112307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of cyclin D2 shRNA on the proliferation and apoptosis of LP-1 cell].
    Guo C; Hou J; Chen YB; Jin HY; Fu WJ; Yuan ZG; Wang DX
    Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):666-9. PubMed ID: 17343197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.